Fidelis is a commercial stage, high-growth potential company offering innovative, proven safe and effective drug delivery.
Additionally, long-acting extended-release technology has the potential to significantly improve animal welfare across a range of species and therapeutic categories.
As shown here, the laboratory animal market is an area of both significant need and high growth potential for pharmaceutical-grade analgesics.
Fidelis is actively seeking new partnerships and product opportunities. If would like to get more information or would like to discuss investment, partnership, or new product development opportunities with the Fidelis leadership team, please contact us using the form on this page. Thank you for your interest.